40-Month PFS? Rethinking First-Line Metastatic HER2+ Therapy with T-DXd - Drs. Mouabbi, O’Shaughnessy & Rimawi

In this in-depth conversation, Dr. Jason Mouabbi, Dr. Joyce O’Shaughnessy, and Dr. Mothaffar Rimawi unpack the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.From DESTINY-Breast 09 to real-world decision-making, they discuss what a 40-month median PFS truly means, how T-DXd compares to THP, and whether “if it ain’t broke, don’t fix it” still applies.They also tackle sequencing strategies, maintenance vs continuous therapy, PIK3CA resistance, and how patient quality of life is shaping long-term treatment decisions.A must-watch episode for clinicians navigating the rapidly evolving HER2+ landscape.#HER2Positive #BreastCancer #TDXd #Oncology #MetastaticBreastCancer #CancerResearch #PrecisionOncology #MedicalOncology #ESMO #ASCO #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media